Protocol Ledger

NCT04489537 · Phase III · TERMINATED

Study of Coagulation Factor VIIa Marzeptacog Alfa (Activated) in Subjects With Hemophilia A or B

Interventional Phase III clinical trial protocol NCT04489537 sponsored by Catalyst Biosciences in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2021-05-04 Enrollment: 18 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04489537
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)18 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04489537
Protocol FieldVerified Registry Value
NCT IdentifierNCT04489537
Consolidated Lead SponsorCatalyst Biosciences
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase III
Overall Recruitment StatusTERMINATED
Registered Enrollment18 participants (ACTUAL)
Registered Start Date2021-05-04
WhyStopped ClassificationSafety / Toxicity / Adverse Events

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT04489537
Hospital Research SiteLocationSite Profile
Phoenix Children's HospitalPhoenix, AZOpen Hospital Dossier ->
Azienda Ospedaliero Universitaria CareggiFlorence, ItalyOpen Hospital Dossier ->
Azienda Ospedaliera Universitaria Federico IINaples, ItalyOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI